Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by educational grants from AstraZenaca Pharmaceuticals LP, Celegene Corporation, Genentech Inc., Genomic Health Inc., and Novartis Corporation.
2018 Year in Review™: Reflecting on Recent Evidence for the Treatment of Breast Cancer
Release Date: April 9, 2019
Expiration Date: April 9, 2020
Media: Internet - based
This Year in Review activity will cover exciting data reported in 2018 at major society meetings with the potential to impact your care of patients with breast cancer. Recent advances in breast cancer include emerging options in targeted therapies, immunotherapeutic strategies, novel combination therapies, and efforts to personalize care. This activity features a panel of experts who will review the key points of clinical trial design and safety, as well as efficacy data, while contextualizing this new information into optimized patient care. Emerging data across the spectrum of breast cancer management will be reviewed and discussed, from early stage to metastatic disease. In addition, our panel of experts will discuss how they are applying this information to their practice right now, as well as its potential future implications.
Benefits of Participation:
- Learn about emerging data for targeted therapies in breast cancer, including AKT and PI3K inhibitors, emerging data for CDK4/6 inhibitors, and an antibody-drug conjugate, as well as new trial data for immunotherapies and PARP inhibitors.
- Benefit from expert guidance on interpreting emerging data and applying new information to the care of your patients with breast cancer.
- Contextualize emerging information on personalizing care based on individual patients with breast cancer and their tumor characteristics.
Acknowledgement of Commercial Support
This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Genentech Inc., Genomic Health Inc., and Novartis Corporation.
Instructions for This Activity and Receiving Credit
This educational activity is directed toward medical oncologists, surgical oncologists, and radiation oncologists involved in the treatment and management of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of cancer are also invited to participate.
Upon successful completion of this activity, you should be better prepared to:
- Explain the design and endpoints of recently reported and ongoing clinical trials evaluating novel strategies for the management of breast cancer
- Detail safety and efficacy data on novel therapeutic strategies that impact the future treatment of breast cancer
- Place emerging evidence into its proper clinical context concerning emerging treatment strategies across the spectrum of disease stages and breast cancer tumor types
Faculty, Staff, and Planners' Disclosures
Clinical Director, Breast Medicine Service
Section Head, Triple Negative Breast Cancer Clinical Research Program
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College
New York, NY
Disclosures: Consultant: Genentech/Roche, Eisai, Medivation, Pfizer, AstraZeneca, Merck, Astellas Pharma, Puma Biotechnology, Advaxis, Celgene, Innocrin Pharmaceuticals, Genomic Health, Bristol-Myers Squibb, Samsung; Speakers Bureau: Genentech/Roche; Research Funding: Medivation, Eisai, Pfizer, Novartis, Innocrin Pharmaceuticals, AstraZeneca, Astellas Pharma
Massachusetts General Hospital Cancer Center
Harvard Medical School
Disclosures: Grant/Research Support: Including institution: Biotheranostics, Genentech/Roche, Immunomedics, Novartis, Pfizer, Merck, Radius Health, Mersana, Sanofi; Consultant: Genentech/Roche, Immunomedics, Novartis, Pfizer, Merck, Radius Health, Spectrum Pharma, Taiho Pharmaceutical, Sanofi, Daiichi-Sankyo.
Co-Director, Breast Cancer Program
Lombardi Comprehensive Cancer Center
Disclosures: Grant/Research Support: Tesaro (to institution); Consultant: AstraZeneca, Genentech, Pfizer, Context, Syndax, PUMA; Speakers Bureau: Genentech, Pfizer.
The staff of PER® have no relevant financial relationships with commercial interests to disclose.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/Ce activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.